External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>XtalPi’s revenue increased by 52.8% YoY to RMB266mn in FY24, driven by strong growth in its intelligent robotics solutions segment, which rose by 87.8% to RMB163mn.</li><li>This was largely due to robust demand of XtalPi R&amp;D solutions, including traditional Chinese medicine (TCM) and electrolyte robotics offerings, as well as increased revenue from automated chemical synthesis services.</li><li>During the period, revenue from drug discovery solutions also grew by 18.2% YoY to RMB104mn, supported by an expanded customer base and a higher number of revenue-generating programs. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

XtalPi’s revenue increased by 52.8% YoY to RMB266mn in FY24, driven by strong growth in its intelligent robotics solutions segment, which rose by 87.8% to RMB163mn.This was largely due to robust demand of XtalPi R&amp;D solutions, including traditional Chinese medicine (TCM) and electrolyte robotics offerings, as well as increased revenue from automated chemical synthesis services.During the period, revenue from drug discovery solutions also grew by 18.2% YoY to RMB104mn, supported by an expanded customer base and a higher number of revenue-generating programs. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

XtalPi (2228 HK) - AI-Driven Innovation Unlocks Expansive Commercial Prospects

<ul><li>Accelerating the design and discovery of novel drugs and materials leveraging quantum physics, AI and robotic automation.</li><li>Founded by three MIT-trained physicists, QuantumPharm Inc. is a globally leading, quantum physics-based, AI-powered, and robotics-driven, innovative R&amp;D platform in terms of technological advantages, aiming to accelerate the design and discovery of novel drugs and materials.</li><li>The Company adopts a combination of quantum physics-based first-principles calculation, advanced AI, highperformance cloud computing, and scalable and standardized robotic automation to provide drug and material science R&amp;D solutions and services to global conglomerates and innovative companies in the pharma and material science industries and beyond.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Accelerating the design and discovery of novel drugs and materials leveraging quantum physics, AI and robotic automation.Founded by three MIT-trained physicists, QuantumPharm Inc. is a globally leading, quantum physics-based, AI-powered, and robotics-driven, innovative R&amp;D platform in terms of technological advantages, aiming to accelerate the design and discovery of novel drugs and materials.The Company adopts a combination of quantum physics-based first-principles calculation, advanced AI, highperformance cloud computing, and scalable and standardized robotic automation to provide drug and material science R&amp;D solutions and services to global conglomerates and innovative companies in the pharma and material science industries and beyond.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

QuantumPharm (2228 HK) - Advanced Quantum Physics-Based, AI-Powered and Robotics

China

XtalPi is a biotechnology company that leverages artificial intelligence, quantum physics, and robotics to provide research and development solutions for early-stage drug discovery and material science. Its services include drug discovery solutions and intelligent automation solutions, offering products like XmartChem and PatSight. The company was founded in 2015 and is headquartered in Shenzhen, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

XtalPi (2228 HK) - AI-Driven Innovation Unlocks Expansive Commercial Prospects

XtalPi’s revenue increased by 52.8% YoY to RMB266mn in FY24, driven by strong growth in its intelligent robotics solutions segment, which rose by...

CMB International

QuantumPharm (2228 HK) - Advanced Quantum Physics-Based, AI-Powered and Robotics

Accelerating the design and discovery of novel drugs and materials leveraging quantum physics, AI and robotic automation.

CMB International